Congratulations to gynecologic oncologist Angeles Alvarez Secord, MD, MHSc, on her appointment as president of the American Association of Obstetricians and Gynecologists Foundation (AAOGF).
In her welcome message as incoming president, Dr. Secord stated, "As we transition into the next chapter for our organization, we reflect on our shared commitment and purpose to further enhance, train and sustain the workforce and address gaps in research addressing obstetric and gynecologic health. This is more than an educational goal — it is integral to advance our field and to our future."
The history of the organization extends back generations to 1929, and since 1981 the AAOGF has functioned as the foundation for the American Gynecological and Obstetrical Society (AGOS).
Dr. Secord serves as director of gynecologic oncology clinical trials, associate director of clinical research in gynecologic oncology and principal investigator for NRG Oncology at the Duke Cancer Institute. Her leadership roles include chair of the NRG Oncology Investigator and Career Development Committee and chair of GOG Education and Mentoring. She has also served on the National Cancer Institute (NCI) Institute Ovarian Cancer Task Force and The National Academies of Sciences, Engineering, and Medicine Committee on the Assessment of NIH Research on Women’s Health.
A nationally recognized investigator, Dr. Secord’s research focuses on novel therapeutics and biomarkers for gynecologic cancers and innovative clinical trial designs.
Dr. Secord is the past president of the Mid-Atlantic Gynecologic Oncology Society and the Society of Gynecologic Oncology (SGO). She has received numerous research and leadership awards including SGO Best Clinical Science Award and the Foundation for Women's Cancer Outstanding Service and Dedication Award. In 2019, she founded the Endometrial Cancer Molecularly Targeted Therapy Consortium, which includes more than 25 member institutions. She has authored more than 260 peer-reviewed publications and received over 100 grants including National Institutes of Health funding through the National Cancer Institute since 2014 for translational research awards and clinical trial leadership. Her dedication to clinical investigation, education, and mentoring future oncology leaders reflects a strong commitment to advancing academic medicine.